Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
US Stock MarketDetailed Quotes
TVTX Travere Therapeutic
- 17.630
- +0.930+5.57%
Close Apr 24 16:00 ET
- 17.540
- -0.090-0.51%
Post 17:08 ET
1.57BMarket Cap-4.32P/E (TTM)
17.685High16.760Low1.43MVolume16.760Open16.700Pre Close24.92MTurnover1.89%Turnover RatioLossP/E (Static)88.77MShares25.29052wk High26.51P/B1.33BFloat Cap5.23552wk Low--Dividend TTM75.66MShs Float37.040Historical High--Div YieldTTM5.54%Amplitude0.000Historical Low17.442Avg Price1Lot Size
About Travere Therapeutic Company
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.
Company Profile
SymbolTVTX
Company NameTravere Therapeutic
Listing DateJan 10, 2014
Founded2008
CEODr. Eric M. Dube, PhD
MarketNASDAQ
Employees385
Fiscal Year Ends12-31
Address3611 Valley Centre Drive,Suite 300
CitySan Diego
ProvinceCalifornia
CountryUnited States of America
Zip Code92130
Phone1-888-969-7879
Websitehttp://www.travere.com
Company Executives
- Name
- Position
- Salary
- Dr. Eric M. Dube, PhD
- Director, President and Chief Executive Officer
- 5.20M
- Sandra Calvin
- Senior Vice President and Chief Accounting Officer
- --
- Elizabeth E. Reed
- Chief Legal Officer, General Counsel and Corporate Secretary
- --
- Peter Heerma
- Chief Commercial Officer
- 1.51M
- Christopher Cline
- Chief Financial Officer
- 1.50M
- Dr. William E. Rote, PhD
- Chief Research Officer
- 1.52M
- Dr. Jula Inrig, M.D.
- Chief Medical Officer
- 1.68M
- Gary A. Lyons
- Chairman of the Board
- 262.32K
- Sandra E. Poole
- Independent Director
- 239.82K
- Ruth WilliaBrinkley
- Independent Director
- 234.82K
- Timothy P. Coughlin
- Independent Director
- 254.82K
- Ron Squarer
- Independent Director
- 237.32K
- John A. Orwin, M.B.A.
- Independent Director
- 242.32K
- Jeffrey A. Meckler
- Independent Director
- 249.32K
- Dr. Suzanne L. Bruhn, PhD
- Independent Director
- 242.32K
- Dr. Roy D. Baynes, M.D.,PhD
- Independent Director
- 247.32K
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
